Allergan Defends 3-Month Exclusivity Deal For Namenda
Pharmaceutical patent holders that sue generic-drug manufacturers for infringement and then shorten product exclusivity periods via settlements shouldn't have to actually win those cases to maintain exclusivity, an Allergan unit told...To view the full article, register now.
Already a subscriber? Click here to view full article